A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa
Clinical trial NCT03060629 · TERMINATED
Trial details
- NCT number
- NCT03060629
- Sponsor
- Janssen Vaccines & Prevention B.V.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-03
- Primary completion
- 2022-02-02
- Enrollment
- 2636
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.